DAFTAR PUSTAKA

Aapro, M., Gascón, P., Patel, K., Rodgers, G.M., Fung, S., Arantes, L.H. dan Wish, J., 2019. Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: A historical perspective. *Frontiers in Pharmacology*, 9, hal.1–10.

Abdelgawad, A., Ghazawy, E., Mohammed, E. dan Mahfouz, E., 2021. Clinical Characteristics of Congenital Anomalies of the Kidney and Urinary Tract, Minia District. *Mini Journal of Medical Research*, 32(4), hal.13–17.

Amanullah, F., Malik, A.A. dan Zaidi, Z., 2022. Chronic kidney disease causes and outcomes in children: Perspective from a LMIC setting. *PLoS ONE*, 17(6), hal.1–11.

Astor, B.C., Muntner, P., Levin, A., Eustace, J.A. dan Coresh, J., 2002. Association of Kidney Function With Anemia. *Archives of Internal Medicine*, 162(12), hal.1401.

Atkinson, M. dan Furth, S., 2017. Anemia in children with chronic kidney disease. *Nature Reviews Nephrology*, 7(11), hal.635–641.

Azizi, M., Rousseau, A., Ezan, E., Guyene, T.T., Michelet, S., Grognet, J.M., Lenfant, M., Corvol, P. dan Ménard, J., 1996. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. *Journal of Clinical Investigation*, 97(3), hal.839–844.

Babitt, J.L. dan Lin, H.Y., 2012. Mechanisms of anemia in CKD. *Journal of the American Society of Nephrology*, 23(10), hal.1631–1634.

Bamgbola, O.F., Kaskel, F.J. dan Coco, M., 2009. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. *Pediatr Nephrol*, 24(3), hal.571–579.

Belsha, C.W. dan Berry, P.L., 1998. Effect of hyperparathyroidism on response to erythropoietin in children on dialysis. *Pediatr Nephrol*, 12(4), hal.298–303.

Brandt, J.R., Avner, E.D., Hickman, R.O. dan Watkins, S.L., 1999. Safety and efficacy of erythropoietin in children with chronic renal failure. *Pediatr Nephrol*, 13(2), hal.143–147.

Brickman, A.S., Sherrard, D.J., Jowsey, J., Singer, F.R., Baylink, D.J., Maloney, N., Massry, S.G., Norman, A.W. dan Coburn, J.W., 1974. 1,25-Dihydroxycholecalciferol Effect on Skeletal Lesions and Plasma Parathyroid Hormone Levels in Uremic Osteodystrophy. *Arch Intern Med*, 134(22), hal.883–888.

Bruce, G., Schulga, P. dan Reynolds, B.C., 2022. Use of erythropoiesis-stimulating agents in children with chronic kidney disease: A systematic review. *Clin Kidney J*, 15(8), hal.1483–1505.

Bunn, H.F., 2013. Erythropoietin. *Cold Spring Harbor Perspectives in Medicine*, 3(3), hal.1–20.

Can, C., Emre, S., Bilge, I., Yilmaz, A. dan Şirin, A., 2013. Comparison of recombinant human erythropoietin and darbepoetin alpha in children. *Pediatr Int*, 55(3), hal.296–299.

Chavers, B.M., Roberts, T.L., Herzog, C.A., Collins, A.J. dan St. Peter, W.L., 2004. Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. *Kidney Int*, 65(1), hal.266–273.

Collins, A.J. et al., 2007. United States Renal Data System 2006 Annual Data Report Abstract. *Am J Kidney Dis*, 49(1).

Van Damme-Lombaerts, R. dan Herman, J., 1999. Erythropoietin treatment in children with renal failure. *Pediatr Nephrol*, 13(2), hal.148–152.

Dhayef, A.K., Manuti, J.K. dan Abutabiekh, A.S., 2017. Anemia response to Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) versus Epoetin Alfa (Eprex) in patients with chronic Kidney disease on Hemodialysis. *J Clin Nephrol*, 1(1), hal.041–047.

Dian, N., Andayani, T.M., Endarti, D., Klinik, M.F., Farmasi, F. dan Mada, U.G., 2022. Cost Effectiveness Analysis (CEA) Strategi Terapi Anemia Pada Pasien Penyakit Ginjal Kronis. *JMPF*, 12(3), hal.164–175.

Fehr, T., Ammann, P., Garzoni, D., Korte, W., Fierz, W., Rickli, H. dan Wüthrich, R.P., 2004. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. *Kidney Int*, 66(3), hal.1206–1211.

Fishbane, S. dan Spinowitz, B., 2018. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. *Am J Kidney Dis*, 71(3), hal.423–435.

Gallieni, M., Corsi, C. dan Brancaccio, D., 2000. Hyperparathyroidism and anemia in renal failure. *Am J Nephrol*, 20(2), hal.89–96.

Gaweda, A.E., Goldsmith, L.J., Brier, M.E. dan Aronoff, G.R., 2010. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. *Clin J Am Soc Nephrol*, 5(4), hal.576–581.

Gerardi, C. dan Bertele, V., 2017. WHO. Application for erythropoietin-stimulating agents (erythropoietin type blood factors). hal.1–46.

Gillespie, R.S. dan Wolf, F.M., 2004. Intravenous iron therapy in pediatric hemodialysis patients: A meta-analysis. *Pediatr Nephrol*, 19(6), hal.662–666.

Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O'Callaghan, C.A., Lasserson, D.S. dan Hobbs, R., 2016. Global Prevalence of Chronic Kidney Disease: A Systematic Review and Meta-Analysis. *Clin Nephrol*, 71(3), hal.244–254.

Hogg, R.J. et al., 2003. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: Evaluation, classification, and stratification. *Pediatrics*, 111(6 I), hal.1416–1421.

Icardi, A., Paoletti, E., De Nicola, L., Mazzaferro, S., Russo, R. dan Cozzolino, M., 2013. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: The potential role of inflammation. *Nephrol Dial Transplant*, 28(7), hal.1672–1679.

IDAI, 2017. *Buku Ajar Nefrologi Anak* Ed Ketiga., Badan Penerbit IDAI.

Jander, A. et al., 2012. Anaemia treatment in chronically dialysed children: A multicentre nationwide observational study. *Scan J Urol and Nephrol*, 46(5), hal.375–380.

KDIGO, 2012. Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Official Journal of the International Society of Nephrology*, 2(4).

Kementerian Kesehatan RI, 2021. *Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/6485/2021 Tentang Formularium Nasional*,

Kementerian Kesehatan RI, 2018. *Peran Pemerintah dalam Pencegahan dan Pengendalian Gagal Ginjal pada Anak*,

Koulouridis, I., Alfayez, M., Trikalinos, T.A., Balk, E.M. dan Jaber, B.L., 2013. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: A metaregression analysis. *Am J Kidney Dis*, 61(1), hal.44–56.

Lee, K.H. et al., 2019. Anemia and iron deficiency in children with chronic kidney disease (CKD): Data from the know-ped CKD study. *J Clin Medicine*, 8(2), hal. 141.

Locatelli, F., Canaud, B., Giacardy, F., Martin-Malo, A., Baker, N. dan Wilson, J., 2003. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo) (Nephrology Dialysis Transplantation (2003) vol. 18 (362-369)). *Nephrol Dial Transplant*, 18(9), hal.1954.

Locatelli, F., Pozzoni, P. dan DelVecchio, L., 2009. Recombinant human epoetin beta in the treatment of chemotherapy-related anemia. *Therapeutics and Clinical Risk Management*, 5(1), hal.261–270.

Macdougall, I.C. dan Cooper, A.C., 2002. Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. *Nephrol Dial Transplant*, 17(11), hal.39–43.

Malyszko, J. dan Mysliwiec, M., 2007. Hepcidin in anemia and inflammation in chronic kidney disease. *Kidney and Blood Pressure Research*, 30(1), hal.15–30.

Masalskienė, J., Rudaitis, Š., Vitkevič, R., Čerkauskienė, R., Dobilienė, D. dan Jankauskienė, A., 2021. Epidemiology of Chronic Kidney Disease in Children: A Report from Lithuania. *Medicina (Lithuania)*, 57(2), hal.112.

Means, R.T., 2004. Hepcidin and cytokines in anaemia. *Hematology*, 9(5–6), hal.357–362.

Van Der Meer, P., Lipsic, E., Westenbrink, B.D., Van De Wal, R.M.A., Schoemaker, R.G., Vellenga, E., Van Veldhuisen, D.J., Voors, A.A. dan Van Gilst, W.H., 2005. Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. *Circulation*, 112(12), hal.1743–1747.

Mircescu, G., Gârneaţă, L., Căpuşă, C. dan Ursea, N., 2006. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. *Nephrol Dial Transplant*, 21(1), hal.120–124.

Mrug, M., Stopka, T., Julian, B.A., Prchal, J.F. dan Prchal, J.T., 1997. Angiotensin II stimulates proliferation of normal early erythroid progenitors. *J Clin Investigation*, 100(9), hal.2310–2314.

Ogawa, T. dan Nitta, K., 2015. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients. *Contributions to Nephrology*, 185, hal.76–86.

Orr, N.I.T., McDonald, S.P., McTaggart, S., Henning, P. dan Craig, J.C., 2009.

Frequency, etiology and treatment of childhood end-stage kidney disease in Australia and New Zealand. *Pediatr Nephrol*, 24(9), hal.1719–1726.

Palmer, S.C., Saglimbene, V., Craig, J.C., Navaneethan, S.D. dan Strippoli, G.F.M., 2014. Darbepoetin for the anaemia of chronic kidney disease. *Cochrane Database of Systematic Reviews*, (3), hal.1465–1858.

Palmer SC, S., Saglimbene, V., Mavridis, D., Salanti, G., Craig, J., Tonelli, M., Wiebe, N. dan Strippoli, G., 2014. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis (Review). *Cochrane Database of Systematic Reviews*, (12), hal 1456-1478.

Patil, R.G., Bhosle, D.G. dan Malik, R.A.H., 2016. Vitamin B12 Deficiency In Chronic Kidney Disease. *IOSR J Dental and Med Sci*, 15(09), hal.22–25.

Pfeffer, M.A., Burdmann, E.A., Chen, C.-Y. dan Cooper, M.E., 2019. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. *The New England Journal of Medicine*, 361(21), hal.2019–2032.

Pinarbasl, A.S., Dursun, I., Günay, N., Baatar, B., Yel, S., Dursun, J., Balaban, A.G., Poyrazoğlu, M.H. dan Düşünsel, R., 2021. Erythropoietin Resistance Index and the Affecting Factors in Children with Peritoneal Dialysis. *Blood Purification*, 50(6), hal.942–951.

Port, R.E. dan Mehls, O., 2009. Erythropoietin dosing in children with chronic kidney disease : based on body size or on hemoglobin deficit ? *Pediatric Nephrologyr*, 24, hal.435–437.

Portolés, J., Martín, L., Broseta, J.J. dan Cases, A., 2021. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. *Frontiers in Medicine*, 8(March), hal.1–14.

Van Der Putten, K., Braam, B., Jie, K.E. dan Gaillard, C.A.J.M., 2008. Mechanisms of Disease: Erythropoietin resistance in patients with both heart and kidney failure. *Nature Clin Practice Nephrol*, 4(1), hal.47–57.

Qie, S., Jiao, N., Duan, K., Li, J., Liu, Y. dan Liu, G., 2021. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review. *Int Urol Nephrol*, 53(5), hal.985–997.

Regidor, D.L., Kopple, J.D., Kovesdy, C.P., Kilpatrick, R.D., McAllister, C.J., Aronovitz, J., Greenland, S. dan Kalantar-Zadeh, K., 2006. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. *Clin J Am Soc Nephrol*, 17(4), hal.1181–1191.

Sihombing, J.P., Hakim, L., Andayani, T.M. dan Irijanto, F., 2019. Cost effectiveness analysis eritropoetin alfa dibandingkan dengan eritropoetin beta pada pengobatan anemia pasien penyakit ginjal kronik. *JMPF*.

Singh, A.K., Szczech, L., Tang, K.L., Barnhart, H., Sapp, S., Wolfson, M. dan Reddan, D., 2006. Correction of anemia with epoetin alfa in chronic kidney disease. *New England Journal of Medicine*, 355(20), hal.2085–2098.

Singh, A.K., Szczech, L., Tang, K.L., Barnhart, H., Sapp, S., Wolfson, M. dan Reddan, D., 2006. Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease. *New England Journal of Medicine*, 355(20), hal.2085–2098.

Staples, A.O., Wong, C.S., Smith, J.M., Gipson, D.S., Filler, G., Warady, B.A.,

Martz, K. dan Greenbaum, L.A., 2009. Anemia and risk of hospitalization in pediatric chronic kidney disease. *Clin J Am Soc Nephrol*, 4(1), hal.48–56.

Stenvinkel, P., 2001. Inflammatory and atherosclerotic interactions in the depleted uremic patient. *Blood Purification*, 19(1), hal.53–61.

Taniguchi, S., Dai, C., Price, J.O. dan Krantz, S.B., 1997. Interferon Gamma Downregulates Stem Cell Factor and Erythropoietin Receptors But Not Insulin-Like Growth Factor-I Receptors in Human Erythroid Colony-Forming Cells. *Blood*, 90(6), hal.2244–2252.

Thaweethamcharoen, T., Sakulbumrungsil, R., Nopmaneejumruslers, C. dan Vasuvattakul, S., 2014. Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis. *Value in Health Regional Issues*, 3(1), hal.44–49.

Warady, B.A., Arar, M.Y., Lerner, G., Nakanishi, A.M. dan Stehman-Breen, C., 2006. Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease. *Pediatr Nephrol*, 21(8), hal.1144–1152.

Weiss, L.G., Clyne, N., Fihlho, J.D., Frisenette-fich, C. dan Kurkus, J., 2019. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin b : results from a randomized controlled multicentre trial. *Int Nephrol Dial Transplant*, hal.2014–2019.

Wish, J.B., 2021. Treatment of Anemia in Kidney Disease: Beyond Erythropoietin. *Kidney International Reports*, 6(10), hal.2540–2553.

Wong, H., Mylrea, K., Feber, J., Drukker, A. dan Filler, G., 2006. Prevalence of complications in children with chronic kidney disease according to KDOQI. *Kidney International*, 70(3), hal.585–590.

Wright, D.G., Wright, E.C., Narva, A.S., Noguchi, C.T. dan Eggers, P.W., 2015. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States. *Clin J Am Soc Nephrol*, 10, hal.1822–1830.

Zaritsky, J. et al., 2009. Hepcidin - A potential novel biomarker for iron status in chronic kidney disease. *Clin J Am Soc Nephrol*, 4(6), hal.1051–1056.